BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15135787)

  • 1. Biochemical markers of acromegaly: GH vs. IGF-I.
    Barkan AL
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S97-100. PubMed ID: 15135787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are there alternative tests for diagnosis of acromegaly?
    Popovic V
    J Endocrinol Invest; 2005; 28(11 Suppl International):73-4. PubMed ID: 16625850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current diagnostic guidelines for biochemical diagnosis of acromegaly.
    Ferone D; Resmini E; Bocca L; Giusti M; Barreca A; Minuto F
    Minerva Endocrinol; 2004 Dec; 29(4):207-23. PubMed ID: 15765030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical evidence in favor of revising Cortina criteria.
    Webb SM; Sucunza N; Barahona MJ
    J Endocrinol Invest; 2005; 28(11 Suppl International):84-6. PubMed ID: 16625854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of Cortina criteria for the diagnosis of acromegaly.
    degli Uberti EC; Bondanelli M; Ambrosio MR; Zatelli MC
    J Endocrinol Invest; 2005; 28(11 Suppl International):70-2. PubMed ID: 16625849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
    Minuto F; Resmini E; Boschetti M; Arvigo M; Sormani MP; Giusti M; Ferone D; Barreca A
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of reference values for endocrine tests--part V: acromegaly.
    Endert E; van Rooden M; Fliers E; Prummel MF; Wiersinga WM
    Neth J Med; 2006; 64(7):230-5. PubMed ID: 16929084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic challenges in acromegaly: a case-based review.
    Bonert V
    Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23 Suppl 1():S23-30. PubMed ID: 20129191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical evidence supporting the Cortina criteria.
    von Werder K
    J Endocrinol Invest; 2005; 28(11 Suppl International):81-3. PubMed ID: 16625853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF-I and mortality in patients with acromegaly.
    Strasburger CJ
    J Endocrinol Invest; 2005; 28(11 Suppl International):78-80. PubMed ID: 16625852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of acromegaly: state of the art.
    Kannan S; Kennedy L
    Expert Opin Med Diagn; 2013 Sep; 7(5):443-53. PubMed ID: 23971897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical laboratory indices in the treatment of acromegaly.
    Clemmons DR
    Clin Chim Acta; 2011 Feb; 412(5-6):403-9. PubMed ID: 21075098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative plasma active and total ghrelin levels are reduced in acromegaly when compared with in nonfunctioning pituitary tumours even after normalization of serum GH.
    Kawamata T; Inui A; Hosoda H; Kangawa K; Hori T
    Clin Endocrinol (Oxf); 2007 Jul; 67(1):140-4. PubMed ID: 17466003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of measurements of insulin-like growth factor 1.
    Clemmons DR
    Nat Clin Pract Endocrinol Metab; 2006 Aug; 2(8):436-46. PubMed ID: 16932333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status.
    Espinosa-de-Los-Monteros AL; Sosa E; Cheng S; Ochoa R; Sandoval C; Guinto G; Mendoza V; Hernández I; Molina M; Mercado M
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):245-9. PubMed ID: 16487431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
    Bastemir M; Akin F; Yaylali GF
    Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
    Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice.
    Pokrajac A; Wark G; Ellis AR; Wear J; Wieringa GE; Trainer PJ
    Clin Endocrinol (Oxf); 2007 Jul; 67(1):65-70. PubMed ID: 17437512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.